Aveva Drug Delivery Systems Wins Appeal, Readies Generic ZTlido® Launch

Aveva Drug Delivery Systems Wins Legal Battle

In a significant legal victory, Aveva Drug Delivery Systems, Inc., a member of the DifGen Pharmaceuticals family, has recently secured a favorable ruling from the U.S. Court of Appeals for the Federal Circuit. The court upheld a previous decision stating that Aveva's proposed generic version of Scilex Pharmaceuticals' ZTlido®—a topical lidocaine product—does not infringe on several patents owned by Scilex. This development positions Aveva on the brink of launching its generic product, which will enjoy 180 days of market exclusivity, a crucial advantage in the competitive pharmaceutical landscape.

Understanding the Legal Proceedings

The legal battle began in June 2022 when Scilex Pharmaceuticals, along with its partners ITOCHU Chemical Frontier Corp. and Oishi Koseido Co., Ltd., filed a lawsuit against Aveva in the Southern District of Florida after Aveva submitted an Abbreviated New Drug Application (ANDA). This filing included a Paragraph IV certification that contested the validity of Scilex's patents related to the ZTlido product.

In July 2024, after a thorough bench trial, the district court found in favor of Aveva, concluding that the proposed generic formulation neither literally infringed nor infringed under the doctrine of equivalents concerning Scilex's U.S. Patent Nos. 9,283,174, 9,925,264, and 9,931,403. No damages or injunctive relief were awarded to Scilex, prompting them to appeal the decision in March 2025.

Aveva's legal team, led by Joseph Thomas Jaros from Rakoczy Molino Mazzochi Siwik LLP, presented a compelling case that ultimately convinced the appellate court to affirm the lower court's ruling. This decision clears Aveva's path to market its generic version of ZTlido, expected to be a game-changer in pain management therapies, especially for patients relying on topical lidocaine treatments.

Looking Ahead: Implications for Aveva

The Federal Circuit's affirmation is not only a triumph for Aveva but also sets a precedent for the pharmaceutical industry regarding patent litigations involving generic drugs. As Aveva prepares for the imminent launch of its generic lidocaine topical system 1.8%, stakeholders are optimistic about the potential market impact and the expanded availability of affordable pain relief options.

Aveva specializes in the development and manufacturing of a variety of dosage forms, including Transdermal Delivery Systems (TDS) and Oral Dissolvable Films (ODF). With licenses enabling them to manufacture and market over-the-counter (OTC) products, Aveva operates from an extensive facility in Miramar, Florida, covering a total area of 210,000 square feet. This strategic capacity places them in a robust position to scale their operations in response to incoming demand once the generic product hits the shelves.

A Broader Look at DifGen Pharmaceuticals

DifGen Pharmaceuticals, the parent company of Aveva, is known for its commitment to creating and delivering high-quality generics that meet complex and specialized pharmaceutical needs. Focused on increasing accessibility to medication, DifGen endeavors to confront the traditional barriers in pharmaceutical product development, striving for innovation that yields competitive advantages in regulatory compliance, clinical affairs, and commercial strategy.

As Aveva stands ready to launch, the anticipated influx of generic lidocaine products evidences the ongoing shift towards more accessible healthcare solutions that balance quality with affordability.

Roberta Loomar, Global General Counsel, has indicated that Aveva is gearing up for the launch and is open to queries regarding this announcement, reflecting the company's readiness to answer the market's questions as the launch date approaches.

In summary, Aveva Drug Delivery Systems' recent court victory not only reaffirms its position in the market but also underlines the critical role generics play in enhancing patient access to essential medications.